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and Maria Rescigno, PhDa,g Milan and Pavia, Italy, and D€usseldorf, GermanyBackground: Thymic stromal lymphopoietin (TSLP) is a
cytokine with pleiotropic functions in the immune system. It has
been associated with allergic reactions in the skin and lungs but
also homeostatic tolerogenic responses in the thymus and gut.
Objective: In human subjects TSLP is present in 2 isoforms,
short and long. Here we wanted to investigate the differential
expression of the TSLP isoforms and discern their biological
implications under homeostatic or inflammatory conditions.
Methods: We evaluated the expression of TSLPs in tissues from
healthy subjects, patients with ulcerative colitis, patients with
celiac disease, and patients with atopic dermatitis and on
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http://dx.doi.org/10.1016/j.jaci.2015.04.011or after stimulation. We then tested the immune activity of
TSLP isoforms both in vitro and in vivo.
Results: We showed that TSLP isoforms are responsible for 2
opposite immune functions. The short isoform is expressed
under steady-state conditions and exerts anti-inflammatory
activities by affecting the capacity of PBMCs and dendritic cells
to produce inflammatory cytokines. Moreover, the short isoform
TSLP ameliorates experimental colitis in mice and prevents
endotoxin shock. The long isoform of TSLP is proinflammatory
and is only expressed during inflammation. The isoforms are
differentially regulated by pathogenic bacteria, such as
Salmonella species and adhesive-invasive Escherichia coli.
Conclusions: We have solved the dilemma of TSLP being both
homeostatic and inflammatory. The TSLP isoform ratio is
altered during several inflammatory disorders, with strong
implications in disease treatment and prevention. Indeed,
targeting of the long isoform of TSLP at the C-terminal portion,
which is common to both isoforms, might lead to unwanted side
effects caused by neutralization of the homeostatic short
isoform. (J Allergy Clin Immunol 2015;136:413-22.)
Key words: Thymic stromal lymphopoietin, gut homeostasis, skin
homeostasis, anti-inflammatory drugs, ulcerative colitis, celiac dis-
ease, atopic dermatitis
Allergic and inflammatory diseases of the skin, airways, and
gut affect millions of persons worldwide, and it is becoming clear
that these diseases can be pathophysiologically connected. For
instance, 70% of patients with atopic dermatitis (AD) undergo
development of asthma through a process called the atopic
march,1 and similarly, it has been hypothesized that exposure to
food allergens through a disrupted skin barrier early in life leads
to antigen sensitization and food allergy.2 Hence there is a link be-
tween skin, airway, and gut inflammatory disorders.
Thymic stromal lymphopoietin (TSLP) is a cytokine involved
in several physiologic and pathologic immune activities.3,4 TSLP
has homeostatic activities because it is expressed by Hassal cor-
puscles in the thymus and regulates the capacity of dendritic cells
(DCs)5 and plasmacytoid DCs6 to drive the development of natu-
ral regulatory T cells. TSLP can also promote the homeostatic
polyclonal expansion of T cells in the absence of foreign antigen.7
In the gut we have shown that TSLP is expressed by intestinal
epithelial cells and educates noninflammatory DCs that have
reduced ability to produce IL-12p708 and drive the differentiation
of inducible regulatory T cells.9
Conversely, TSLP has been shown to play a pathogenic role in
several immune disorders, including AD, asthma, and food413
J ALLERGY CLIN IMMUNOL
AUGUST 2015
414 FORNASA ET ALAbbreviations usedAD: Atopic dermatitisCD: Celiac diseaseDC: Dendritic cellDSS: Dextran sodium sulfatelTSLP: Long isoform thymic stromal lymphopoietinMAPK: Mitogen-activated protein kinasemDC: Myeloid dendritic cellmoDC: Monocyte-derived dendritic cellNF-kB: Nuclear factor kBpoly I:C: Polyinosinic:polycytidylic acidshTSLP: Short isoform thymic stromal lymphopoietinSTAT5: Signal transducer and activator of transcription 5TLR: Toll-like receptorTSLP: Thymic stromal lymphopoietinTSLPR: Thymic stromal lymphopoietin receptorUC: Ulcerative colitisallergy.4 Indeed, TSLP can drive the development of strong
allergic TH2 responses with release of IL-4, IL-5, IL-13, and
TNF-a10 through upregulation of OX40 ligand expression on
TSLP-treated DCs.11 TSLP is overexpressed in the airways of
asthmatic patients and is associated with TH2 cytokines.
12,13
TSLP is directly involved in the itch response,14 in activating
innate lymphoid cells to induce skin inflammation,15 and in the
atopic march.16 Consistently, TSLP polymorphisms are linked
to asthma susceptibility17-19 and AD.20,21 TSLP influences the
differentiation of basophils, which are more prone to promote
TH2 inflammation
22 and involved in eosinophilic esophagitis.23
Hence it seems that TSLP has both physiologic and pathologic
activities that are difficult to reconcile. Here we show that this
dichotomy can be explained by the presence of 2 distinct isoforms
of TSLP, a long and a short one, which are differentially regulated
and involved in inflammatory and anti-inflammatory responses,
respectively.
METHODS
Tissue sampling
Intestinal mucosa was excised from the intestines of patients with ulcerative
colitis (UC) at the time of surgery (n 5 13). As a control, intestinal samples
were obtained from healthy tissue (at least 7 cm away from neoplastic tissue) of
patients undergoing surgery for colon cancer (n5 26). The mucosal layer was
separated from the rest of the tissue by a pathologist and directly transferred to
our laboratory. Transfer was carried out in both cases in HBSS buffer at 48C
supplemented with bacteriostatic antibiotics. Mucosa from patients with celiac
disease (CD) was obtained by means of biopsy during routine colonoscopy
(patients with treated CD, n5 15; patients with untreated CD, n5 13; healthy
subjects, n 5 13). Skin biopsy specimens were taken from patients with AD;
lesional, nonlesional tissue, and healthy tissue (from the back or the thigh) was
collected (n 5 24). The clinical diagnosis was confirmed by means of
dermatopathologic evaluation. All tissues were obtained from patients who
signed an informed consent form approved by the institutional review board
allowing material not required for diagnosis to be used for research purposes.
The samples were handled in a completely anonymous manner and assigned a
serial number by the pathologist for cross-checking histologic reference.
On the basis of a series of preliminary experiments, the size of samples for
each disease group has been calculated to estimate the statistical differences
with a power of 0.80 and an a value of .05.
Mice
Female C57Bl/6J mice (8-10 weeks of age) were obtained from Charles
River Laboratories (Milan, Italy). Mice were bred and maintained at theIFOM-IEO Campus Animal Facility under specific pathogen-free conditions.
All experiments were performed in accordancewith the guidelines established
in the Principle of Laboratory Animal Care (directive 86/609/EEC).
LPS-induced endotoxic shock
Mice were treated intraperitoneally with short isoform TSLP (shTSLP) at
50, 100, and 200 mg per mouse in 200 mL of injectable water twice (18 hours
and 2 hours) before LPS administration (n 5 8 per group). Control mice
received water. LPS (Escherichia coli serotype 026:B6; Sigma-Aldrich, St
Louis, Mo) was injected intraperitoneally at 200 mg per mouse in 200 mL
of injectable water. After 6 hours, mice were killed by means of
exsanguination after achievement of anesthesia, and blood was collected.
IFN-g, IL-6, and IL-12p40 levels were detected in serum by means of ELISA
(R&D Systems, Minneapolis, Minn).
Dextran sodium sulfate–induced colitis
Colitis was induced by adding 3% (wt/vol) dextran sodium sulfate (DSS;
TdB Consultancy AB, Uppsala, Sweden) to drinking water for 9 days. Mice
were treated intraperitoneally with shTSLP (200 mg in 200 mL of injectable
water) the day before DSS administration and every other day during the entire
study (n 5 12 per group). Mice were monitored daily for weight loss.
Bacterial strains
Salmonella enterica serovar typhimurium SL1344 strain FB62 (hereafter
referred to as Salmonella typhimurium) and E coli strains LF82 and
MG1655 (a kind gift from Arlette Darfeuille-Michaud) were cultured in TB
broth. For infection, bacteria were grown at 378C under agitation until reach-
ing the exponential growth phase (OD between 0.55 and 0.65). Colony-
forming unit numbers were controlled by means of plating.
Statistical analysis
All statistics were performed with a 2-tailed Student t test or 1-way AN-
OVAwith GraphPad Prism software (GraphPad Software, La Jolla, Calif). Sta-
tistical significancewas retained for P values of less than .05.When results are
reported in terms of fold increase, statistical tests were applied to log-
transformed data.
RESULTS
shTSLP is the homeostatic isoform of TSLP and is
constitutively expressed in healthy skin and gut
We carried out an analysis on the UCSC Genome Browser
of human TSLP isoforms. There are 3 transcript variants (RefSeq
database), but only 2 give rise to coding RNAs: the canonical TSLP
transcript variant 1 (NM_033035_hg19 160 chr5:110407589-
110411772) and a transcript variant 2 (NM_138551_hg19 64
chr5:110409281-110411772). The 2 coding transcripts code for
the long isoform of thymic stromal lymphopoietin (lTSLP) of 159
amino acids (variant 1) and for shTSLP (variant 2), which
encompasses the last 63 residues of lTSLP and is identical to its
C-terminal portion (Fig 1,A). They are not alternatively spliced iso-
forms but derive from the activity of 2 putative promoter regions
(Fig 1, A). In Fig 1, A, we portrayed the ENCODE track profiles
showing active enhancers (H3K4me1 high, H3K4me3 low, and
H3K27ac high) or promoters (H3K4me1 low, H3K4me3 high,
and H3K27ac high) in the middle, and at the bottom, we portrayed
the ENCODEDNaseI hypersensitive site clusters derived from 125
cell types and transcription factor binding regions assessed by using
ChIP-seq experiments. This analysis highlights that although the re-
gion upstream from the long isoform under steady-state conditions
is hardly used inmost of the cell lines present in theUCSCdatabase,
the short isoform promoter shows a high capacity to bind a number
of different transcription factors (Fig 1, A). Hence we assessed the
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FIG 1. shTSLP is the predominant isoform expressed on human intestinal and skin tissue.A, Schematic rep-
resentation of the human TSLP locus from the UCSC Genome Browser (hg19). B and C, Quantitative real-
time PCR analysis of shTSLP and lTSLP mRNA in intestinal total tissue, isolated intestinal epithelial cells
(IECs), and lamina propria (LP) cells (Fig 1, B) and skin samples (Fig 1, C) from healthy subjects. ***P < .001.
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Wedesignedprimers specific for either lTSLPor shTSLP (seeTable
E1 in this article’s Online Repository at www.jacionline.org).
Consistently with the data from the genome browser, we detected
much higher levels of shTSLP expression in steady-state conditions
inboth tissues (Fig 1,B andC). Furthermore,we separated intestinal
epithelial cells and lamina propria cells from healthy colonic mu-
cosa and found that shTSLP was predominant in both cases, indi-
cating that neither of these 2 cellular populations preferentially
produces the long isoform under steady-state conditions (Fig 1,
B). Thus we describe that shTSLP is the homeostatic isoform of
TSLP present under steady-state conditions in the gut and skin.shTSLP exerts anti-inflammatory effects in vitro
Cross-talk between epithelial cell and underlying antigen-
presenting cell populations is a key interaction for the maintenance
of tissue homeostasis. We described an important homeostatic role
for intestinal epithelial cell–derived TSLP in controlling the
inflammatory potential of DCs.8,9 However, we always used tools
that would not discriminate which isoform was the one responsible
for this effect. Having shown that shTSLP is the primary isoform
expressed under steady-state conditions,wepostulated that shTSLP
might be homeostatic and anti-inflammatory. To investigate this hy-
pothesis, we cloned the 2 isoforms in insect cells using baculovirus
technology and chemically synthesized the shTSLP (see Fig E1 in
this article’s Online Repository at www.jacionline.org and not
shown). We then cocultured PBMCs from different donors in the
presence of the indicated concentrations of the 2 isoforms (Fig 2,
A). We used IFN-g release in culture supernatants as the mainreadout for the assay. Contrary to lTSLP, the presence of shTSLP
in coculture medium reduced IFN-g release in a dose-dependent
fashion (Fig 2, A). We then analyzed whether shTSLP had anti-
inflammatory properties on DCs. We derived DCs from peripheral
blood monocytes (monocyte-derived dendritic cells [moDCs]) and
incubated them for 24 hours with shTSLP before challenge with
Salmonella typhimurium. We found that shTSLP-conditioned
moDCs were strongly inhibited in their capacity to produce cyto-
kines (Fig 2,B).We found that shTSLP did not affect the phenotype
of mature DCs in response to Salmonella typhimurium (see Fig E2
in this article’s Online Repository at www.jacionline.org).
The molecular pathway of lTSLP signaling is well character-
ized; it mediates its effects after binding to its own receptor, a
complex formed by thymic stromal lymphopoietin receptor
(TSLPR) and the IL-7 receptor a chain,24,25 and phosphorylation
of signal transducer and activator of transcription 5 (STAT5) is a
key downstream event.26 To elucidate the pathways of shTSLP
signaling, we used a human phosphokinase array that analyzes
phosphorylation of 46 intracellular kinases (Human Phospho-
Kinase Array, R&D Systems) after 5 and 20 minutes of stimula-
tion (Fig 3, A). shTSLP induced phosphorylation of a limited
number of molecules, including p38a, extracellular signal-
regulated kinase 1/2, and Lyn, but had only a mild effect on
STAT5 phosphorylation (Fig 3, A). The capacity of shTSLP to
activate p38a was confirmed by means of Western blotting in 4
different moDC donors (Fig 3, B). We then performed the same
kinase array on LPS-stimulated moDCs previously conditioned
or not with shTSLP to assess whether it was modulating
Toll-like receptor (TLR)–mediated signaling. Interestingly, the
level of p38a and extracellular signal-regulated kinase 1/2
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FIG 2. shTSLP has anti-inflammatory properties. A, IFN-g production in a
bidirectional mixed lymphocyte reaction in the presence of shTSLP and
lTSLP. Results of 3 independent experiments are shown. B, Inflammatory
cytokine secretion of moDCs conditioned with shTSLP and then infected
with Salmonella typhimurium. Results of 4 independent experiments are
shown. Data are expressed as a ‘‘fold change’’ considering untreated
PBMCs or cells treated only with Salmonella typhimurium as a control
(value5 1). Significant differences were determined bymeans of 1-way AN-
OVA with the Dunnett test. *P < .05 and **P < .01.
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with shTSLP (see Fig E3 in this article’s Online Repository at
www.jacionline.org), suggesting that it affects LPS-mediated
mitogen-activated protein kinase (MAPK) activation. We could
speculate that the slight phosphorylation of p38 MAPK induced
by shTSLP might either desensitize the cells against further acti-
vation or raise the threshold of moDC activation, thus resulting in
decreased cytokine production after TLR engagement.
moDCs do not express TSLPR, and thus to test the capacity of
both isoforms to induce TSLPR-mediated signaling, we switched
to myeloid blood-isolated CD1c1 DCs that are TSLPR1. We
found that only lTSLP induced STAT5 phosphorylation (Fig 4,
A). This did not exclude the possibility of shTSLP binding to
TSLPR and acting as an antagonist, blocking signal from the
lTSLP. However, when myeloid dendritic cells (mDCs) were stim-
ulated with the 2 isoforms, either alone or together in an equimolar
ratio, shTSLP had no capacity to block or inhibit lTSLP-dependent
STAT5 phosphorylation (Fig 4,A). This suggests that shTSLP doesnot bind to TSLPR and is not dominant negative. Indeed, only
lTSLP significantly upregulated CCL17 and CCL22 expression,
as expected from TSLP activation,10 and this was not affected by
the presence of shTSLP (Fig 4, B). Consistently, lTSLP-
conditioned mDCs were inflammatory and significantly upregu-
lated secretion of TNF-a from naive T cells in an allogeneic mixed
lymphocyte reaction, both in the presence and absence of shTSLP
(Fig 4, C). However, shTSLP is capable of exerting an anti-
inflammatory activity on mDCs because shTSLP-conditioned
mDCswere impaired in inducing IFN-g secretion byT cells during
the mixed lymphocyte reaction (Fig 4,D), a property not shared by
lTSLP (data not shown), indicating that mDCs respond to shTSLP
in an anti-inflammatory way.shTSLP prevents endotoxin shock and ameliorates
experimental colitis in vivo
In the mouse a short TSLP isoform has not been described or
annotated in RefSeq. However, the C-terminal region of mouse
TSLP shares 40% identity with human shTSLP (see Fig E4 in this
article’s Online Repository at www.jacionline.org). Thus
we analyzed whether human shTSLP might have anti-
inflammatory properties also in the mouse in vivo. To this end,
C57/BL6 mice were injected intraperitoneally with shTSLP 18
and 2 hours before injection with LPS. Six hours after LPS injec-
tion, mice were killed, and cytokines were measured in the sera.
Prophylactic injection with shTSLP led to a significant decrease
of IL-6, IL-12/23p40, and IFN-g levels in a dose-dependent
fashion (Fig 5, A). Because we found that in the human gut
TSLP is predominant at steady-state conditions, we assessed
whether it might exert a protective role during gut perturbations,
such as during experimental colitis. We administered shTSLP to
mice every other day to evaluate whether it could protect against
DSS-induced colitis. Mice treated with 200 mg of shTSLP dis-
played significantly reduced weight loss and faster recovery
(Fig 5, B), suggesting a protective role during gut-induced
inflammation.
Taken together, these data support a homeostatic/anti-
inflammatory role of shTSLP in vitro and in vivo.Short/long TSLP ratios are affected in gut disorders
We previously described that intestinal epithelial cells isolated
from patients with Crohn disease have lost the ability to express
TSLP by using primers that do not distinguish between the 2
isoforms.8,9 Knowing that lTSLP is not expressed under steady-
state conditions (Fig 1, B), we now know that the reduction in
TSLP expression was attributable to the lack of shTSLP expres-
sion. Hence we evaluated whether there was a deregulation of
TSLP expression in patients with other inflammatory bowel dis-
orders. We analyzed the expression of TSLP isoforms in cells
isolated from patients with UC and in total tissue biopsy speci-
mens from patients with CD (see Table E2 in this article’s Online
Repository at www.jacionline.org). We found that lTSLP and
TSLPR were significantly upregulated in tissues from patients
with UC compared with levels seen in healthy colonic mucosa,
whereas shTSLP expression was unchanged (Fig 6, A, and see
Fig E5, A, in this article’s Online Repository at www.
jacionline.org). These data were confirmed at the protein level
through immunofluorescence staining and Western blotting
with an antibody directed specifically to lTSLP. We generated
A B
FIG 3. shTSLP increases p38a phosphorylation in moDCs. A, Human phosphokinase array assay of moDCs
left untreated or conditioned for 5 and 20 minutes with 100 ng/mL short TSLP. B, Quantification of p38a
phosphorylation in untreated and shTSLP-stimulated moDCs by means of Western blotting: representative
membranes from 2 donors (upper panel) and quantification analysis of 4 independent donors (lower panel).
Values are normalized against total p38a protein levels and compared with untreated cells.
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that is not present in shTSLP (see Fig E1). This antibody did not
detect any protein in healthy tissue sections, whereas it stained
positive on biopsy specimens from patients with UC (Fig 6, B)
both in the isolated epithelial cell and lamina propria compart-
ments. By contrast, an antibody that recognizes both isoforms
stained positive on healthy tissues, indicating the presence of
shTSLP (Fig 6, B). We used the same antibodies for Western
blot analysis of protein lysates from biopsy specimens of healthy
subjects (n5 9) and patients with UC (n5 9). The antibody that
recognizes both isoforms can be used to identify shTSLP based
on its molecular weight. We confirmed that lTSLP expression
is greatly upregulated in patients with UC. shTSLP is present
in tissues from both healthy subjects and patients with UC, andinterestingly, it shows one additional band (about 6 KDa), prob-
ably because of cleavage, degradation, or both, particularly in
UC samples (see Fig E6 in this article’s Online Repository at
www.jacionline.org). Hence in healthy conditions the only iso-
form expressed is the shTSLP, whereas under inflammation,
the lTSLP appears.
We then analyzed the expression of the 2 isoforms in tissue
from patients with CD either untreated or under a gluten-free diet
(treated). In this case both isoforms were significantly down-
regulated in patients with untreated CD compared with thosewith
treated CD and biopsy specimen from healthy subjects (Fig 6, C).
TSLPR expression instead was not modulated between the groups
(see Fig E5, B). The data are referred to cytokeratin 18 expression
to take into consideration a possible reduction in the number of
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mined by using 1-way ANOVA with the Dunnett test. B, Body weight
changes in mice with DSS-induced colitis treated with shTSLP or vehicle
intraperitoneally. The graph shows the percentage of body weight relative
to initial body weight. *P < .05, **P < .01, and ***P < .001.
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inflammatory disorders are characterized by an alteration of the
ratio between shTSLP and lTSLP.TSLP isoform expression in epithelial cells is
regulated by proinflammatory stimuli
Given the divergent properties of TSLP isoforms, we analyzed
whether there were conditions that affected TSLP expression and
that could be of relevance to the inflammatory gut disorders in
which the ratio of the 2 isoforms is altered. We first assessed basal
levels of expression of the 2 isoforms by the intestinal epithelial
cell line Caco-2 using real-time PCR, and we noticed an identical
trend to the one we observed in primary intestinal epithelial cells
(see Fig E7, A, in this article’s Online Repository at www.
jacionline.org). We confirmed these data also at the protein level
by means of Western blot analysis on noninfected Caco-2 cells
(see Fig E7, B). However, this pattern was completely reversed
when Caco-2 cells were challenged with Salmonella typhimu-
rium. In this case a significant upregulation of lTSLP expression,
accompanied by a downregulation of shTSLP expression, wasobserved (Fig 6, D). A similar trend of lTSLP expression upregu-
lation was observed when we used the adherent-invasive E coli
strain LF82, although this did not reach statistical significance
(Fig 6, D). Interestingly, the E coli nonpathogenic strain
MG1655 had no effect on both isoforms.TSLP isoforms are deregulated in patients with AD
and skin keratinocytes exposed to inflammatory
stimuli
When we analyzed the expression of TSLP isoforms in skin
inflammatory disorders, such as AD, we observed an even more
complex picture. As expected from the literature,10 we found an
upregulation of the lTSLP isoform in lesional as opposed to non-
lesional biopsy specimens (Fig 7, A); unexpectedly, we found that
shTSLP was significantly downregulated in lesional biopsy spec-
imens (Fig 7, A). No difference was observed in TSLPR expres-
sion (see Fig E5, C). Immunofluorescence staining of tissue
sections with the 2 antibodies confirmed the results obtained by
means of qPCR, even though technically we could not demon-
strate a reduction in the expression of shTSLP in lesional skin
(Fig 7, B). This indicates that we have a further unbalance of
the 2 isoforms in patients with AD because we find a concomitant
downregulation of shTSLP and upregulation of lTSLP.
We then examined the effect of proinflammatory and anti-
inflammatory stimuli in the 2 isoforms’ expression on human
primary keratinocytes, HEKa cells. Vitamin D deficiency has been
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Furthermore, putative vitamin D response elements have been
found in the upstream region of lTSLP30 in addition to the well-
known nuclear factor kB (NF-kB)–responsive element that allow
its expression in response to TLR ligands.31 Thus we challenged
HEKa cells,whichwere previously starved for 24 hours, with either
vitamin D3 (10 mmol/L) or polyinosinic:polycytidylic acid
(poly I:C; 5mg/mL), a TLR3 agonist, and we performed chromatinimmunoprecipitation andquantitativePCRanalysis ofH3K27acet-
ylated long and short promoter regions. We observed that the pro-
moter of shTSLP was more active than that of lTSLP in untreated
cells (Fig 7, C). Interestingly, vitamin D3 induced enrichment in
H3K27Ac in the promoter of both lTSLP and shTSLP, resulting
in increased transcription primarily of the shTSLP isoform (Fig 7,
C andD). On the other hand, poly I:C induced H3K27ac deposition
only in the promoter of lTSLP, and this resulted in a stronger
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420 FORNASA ET ALinduction of lTSLPmRNA compared with vitamin D3 stimulation,
even though the acetylation level was lower (Fig 7, C and D). This
indicates that poly I:C and presumably NF-kB activate only the
lTSLP promoter and result in strong lTSLP mRNA transcription.
By contrast, vitaminD3 activates both regions and induces shTSLP
transcription but is not sufficient for lTSLP transcription. A similar
result was obtained with the keratinocyte cell line HaCaT (see Fig
E8 in this article’s Online Repository at www.jacionline.org) and is
consistentwith the literature onprimarykeratinocytes,where anup-
regulation of total TSLPmRNA, but not lTSLPmRNA,was shown
in response to vitamin D3.32 Thus we can conclude that isolated
epithelial cells and skin keratinocytes express lTSLP only in
response to invasive bacteria or proinflammatory stimuli, whereas
expression of shTSLP is constitutive but can be upregulated by
anti-inflammatory mediators (vitamin D3) or downregulated by
pathogenic bacteria (Salmonella typhimurium).DISCUSSION
Here we have shown that the dilemma of TSLP mediating
proinflammatory and anti-inflammatory activities can be explained
by the existence of 2 isoforms of TSLP that are not alternatively
spliced, but each one is driven by a differentially regulated
promoter region. At the protein level, shTSLP encompasses the
last 63 residues of lTSLP. Consistent with a higher activity of
shTSLPpromoter in untreated cells, shTSLP is the primary isoform
expressed under steady-state conditions and is anti-inflammatory
and homeostatic, whereas lTSLP is pathogenic and induced by
inflammatory stimuli. shTSLP does not seem to have antagonistic
activity on lTSLPbut can condition bothmDCs andmoDCs to limit
their inflammatory potential, probably by inducing a suboptimalactivation of MAPK, at least on moDCs. Consistently, shTSLP
does not induce or inhibit signaling through the receptor of lTSLP,
suggesting a signaling pathway that is independent on TSLPR,
which is not expressed on moDCs at steady-state conditions.
The existence of a parallel and molecularly independent
mechanism underlying the anti-inflammatory functions of
shTSLP is fully supported by structural analysis of the murine
TSLP–TSLPR–IL-7 receptor a complex.33 Mouse TSLP, which
is the ortholog of human lTSLP, is 140 residues long and folds
as a 4-helix bundle, stabilized by 3-disulphide bonds and several
hydrophobic interactions contributed by the N-terminal portion of
the protein. Because this region is not present in shTSLP, we pre-
dict that shTSLP adopts a significantly different conformation
than lTSLP, which might explain why it uses a different receptor.
The 3-dimensional structure of mouse and human lTSLP is likely
conserved because most of the residues involved in the scaffold of
TSLP are conserved33 and there is a 40% amino acid identity in
the sequences of the regions corresponding to shTSLP between
mice and human subjects. Hence even though in the mouse there
is no open reading frame for shTSLP, this protein might still be
generated by protease cleavage from lTSLP. Hence it is not sur-
prising that, when tested in mice, human shTSLP could protect
them from endotoxin shock and DSS colitis, suggesting an anti-
inflammatory role in vivo.
The 2 isoforms aremodulated during inflammation. In particular,
invasive pathogenic bacteria, such as Salmonella typhimurium or
adherent-invasive E coli strain, can upregulate the expression of
the lTSLP in intestinal epithelial cells, whereas Salmonella typhi-
murium is also capable of dowregulating shTSLP. Because E coli
with adhesive and invasive capacities has been associated with in-
flammatory bowel disease,34,35 this might explain why there is an
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can activate the promoter and upregulate the expression of shTSLP
in skin keratinocytes. This is an important observation because we
found shTSLP expression to be downregulated in patients with
AD, and a negative correlation between vitamin D3 levels and the
severity of AD has been shown.27-29 Hence one of the mechanisms
of action of vitamin D3 supplementation, which has been shown to
be beneficial in the treatment of AD,36 might be through the re-
establishment of a homeostatic condition through upregulation of
the shTSLP. In patients with CD, we found a downregulation of
TSLP levels that are normalized when patients are on a gluten-
freediet, indicating that this is probablynot a primarydefect in these
patients.
Interestingly, because we found that shTSLP is associated with
the control of inflammatory mediator release both in vitro and
in vivo and with a reduction of IFN-g production, we can hypoth-
esize that conditions leading to a reduction in shTSLP expression
could lead to an uncontrolled TH1 type of responses, such as in
patients with CD. By contrast, when lTSLP is upregulated, such
as in patients with AD and UC, presumably through NF-kB acti-
vation, which is a hallmark of inflammation in both inflammatory
bowel disease and AD,37-39 a TH2 component is induced. In addi-
tion, 2 recent reports have shown an antimicrobial activity of pep-
tides within the shTSLP sequence, indicating a possible
additional homeostatic activity of shTSLP in vivo.40,41 Hence in
a personalized view of treatment for patients with inflammatory
disorders, one should take these 2 aspects into account and might
on the one hand block the inflammatory potential of lTSLP when
this is upregulated and on the other hand re-establish immune ho-
meostasis through administration of shTSLP or drugs involved in
its upregulation, when shTSLP is downregulated. Additionally,
caution should be taken when using in therapy antibodies or bio-
logicals that do not distinguish between the 2 isoforms and that
might elicit unwanted effects by targeting shTSLP.
Key messages
d Human TSLP exists in 2 distinct isoforms: shTSLP and
lTSLP.
d shTSLP is the only isoform expressed in healthy skin and
gut tissue, whereas lTSLP is present in diseased inflam-
matory conditions.
d The shTSLP/lTSLP ratio is altered in patients with UC,
CD, and AD.
d shTSLP, contrary to lTSLP, has an anti-inflammatory ef-
fect both in vitro and in vivo.
d The dual role of TSLP isoforms could explain the litera-
ture paradox of human TSLP being both proinflamma-
tory and tolerogenic.REFERENCES
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